1. Home
  2. SON vs STVN Comparison

SON vs STVN Comparison

Compare SON & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonoco Products Company

SON

Sonoco Products Company

HOLD

Current Price

$53.86

Market Cap

4.7B

ML Signal

HOLD

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$16.04

Market Cap

4.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
SON
STVN
Founded
1899
1949
Country
United States
Italy
Employees
N/A
N/A
Industry
Containers/Packaging
Containers/Packaging
Sector
Consumer Discretionary
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.2B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
SON
STVN
Price
$53.86
$16.04
Analyst Decision
Buy
Hold
Analyst Count
8
2
Target Price
$63.00
$23.75
AVG Volume (30 Days)
1.1M
712.6K
Earning Date
05-20-2026
01-01-0001
Dividend Yield
3.86%
0.36%
EPS Growth
510.30
N/A
EPS
10.07
N/A
Revenue
$7,518,753,000.00
N/A
Revenue This Year
$0.27
$8.42
Revenue Next Year
$1.94
$9.27
P/E Ratio
$5.47
$27.15
Revenue Growth
41.72
N/A
52 Week Low
$38.65
$13.91
52 Week High
$58.44
$28.00

Technical Indicators

Market Signals
Indicator
SON
STVN
Relative Strength Index (RSI) 52.96 47.91
Support Level $43.81 $13.91
Resistance Level $58.44 $16.69
Average True Range (ATR) 1.67 0.83
MACD -0.41 0.24
Stochastic Oscillator 39.19 54.14

Price Performance

Historical Comparison
SON
STVN

About SON Sonoco Products Company

Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Share on Social Networks: